0001209191-22-025515.txt : 20220425 0001209191-22-025515.hdr.sgml : 20220425 20220425161106 ACCESSION NUMBER: 0001209191-22-025515 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220421 FILED AS OF DATE: 20220425 DATE AS OF CHANGE: 20220425 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wolchko J Scott CENTRAL INDEX KEY: 0001586893 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36076 FILM NUMBER: 22849795 MAIL ADDRESS: STREET 1: C/O FATE THERAPEUTICS, INC. STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FATE THERAPEUTICS INC CENTRAL INDEX KEY: 0001434316 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 651311552 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 BUSINESS PHONE: 858.875.1803 MAIL ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-21 0 0001434316 FATE THERAPEUTICS INC FATE 0001586893 Wolchko J Scott C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 1 1 0 0 President and CEO Common Stock 2022-04-21 4 M 0 30000 2.70 A 461546 D Common Stock 2022-04-21 4 S 0 22715 34.57 D 438831 D Common Stock 2022-04-21 4 S 0 4062 35.73 D 434769 D Common Stock 2022-04-21 4 S 0 2220 36.70 D 432549 D Common Stock 2022-04-21 4 S 0 1003 37.90 D 431546 D Common Stock 2022-04-22 4 M 0 10000 2.70 A 441546 D Common Stock 2022-04-22 4 S 0 9162 34.54 D 432384 D Common Stock 2022-04-22 4 S 0 838 35.15 D 431546 D Stock Option (Right to Buy) 2.70 2022-04-21 4 M 0 30000 2.70 D 2027-01-03 Common Stock 30000 46246 D Stock Option (Right to Buy) 2.70 2022-04-22 4 M 0 10000 2.70 D 2027-01-03 Common Stock 10000 36246 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Represents the weighted average sale price of the shares sold from $34.22 to $35.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7. Represents the weighted average sale price of the shares sold from $35.29 to $36.25 per share. Represents the weighted average sale price of the shares sold from $36.29 to $37.08 per share. Represents the weighted average sale price of the shares sold from $37.70 to $38.38 per share. Represents the weighted average sale price of the shares sold from $34.04 to $35.03 per share. Represents the weighted average sale price of the shares sold from $35.04 to $35.29 per share. This option is fully vested. /s/ Cindy Tahl, as Attorney-in-Fact 2022-04-25